GlassScriptPhysician profile
Robert J Bloomberg
NPI 1952375362
$11,821.83
in general payments reported to CMS, 2019-2025
62 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,152 · 2020: $1,645 · 2021: $1,641 · 2022: $1,266 · 2023: $1,191 · 2024: $1,742 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,118.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,320.49 | 2019-2025 | Airsupra, Fasenra, Farxiga |
| Novo Nordisk INC | $1,248.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $996.64 | 2019-2025 | Vraylar, Ubrelvy, Botox |
| Amgen INC. | $908.72 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $651.66 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $603.14 | 2019-2025 | |
| Allergan, INC. | $562.09 | 2019-2021 | |
| Abbott Laboratories | $496.90 | 2021-2025 | Freestyle Libre 3, Proclaim, Jot Dx |
| Lilly USA, LLC | $466.49 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Mylan Specialty L.P. | $297.32 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $296.31 | 2019-2025 | |
| Eisai INC. | $295.55 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.39 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $269.95 | 2019-2022 | |
| Philips North America LLC | $259.65 | 2019-2020 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bloomberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.